Revenue
2010
2011
2012
2013
2014
2015
2016
2018
2019
2020
2021
2022
2023
2024
Zivo Bioscience, Inc. (ZIVO)
Price$3.60Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Free cash flow
2010
2011
2012
2013
2014
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Financial statements
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $157,220 | $27,650 | $0 | $0 | $20,000 | $0 | $0 | — | $0 | $0 | $0 | $0 | $0 | $103,891 | $82,725 |
| Gross profit | $48,952 | $11,610 | $0 | — | — | — | — | — | — | — | — | $0 | $0 | −$34,361 | $30,918 |
| Gross margin | 31.14% | 41.99% | — | — | — | — | — | — | — | — | — | — | — | −33.07% | 37.37% |
| Research & development | $3.1M | $1.4M | $2.2M | $2.0M | $3.8M | $2.3M | $2.8M | $2.4M | $788,971 | $1.0M | $2.0M | $1.0M | $137,000 | $42,000 | $395,573 |
| Operating expenses | $13.4M | $7.3M | $8.7M | $8.6M | $8.6M | $8.4M | $6.1M | $6.3M | $3.5M | $3.1M | $5.2M | $3.1M | $2.1M | $2.0M | $4.1M |
| Operating income | −$13.4M | −$7.3M | −$8.7M | −$8.6M | −$8.6M | −$8.4M | −$6.1M | −$6.3M | −$3.5M | −$3.1M | −$5.2M | −$3.1M | −$2.1M | −$1.9M | −$4.1M |
| Operating margin | −8,498.85% | −26,267.67% | — | — | −42,778.38% | — | — | — | — | — | — | — | — | −1,865.71% | −4,909.09% |
| EBITDA | −$13.4M | −$7.3M | −$8.7M | −$8.6M | −$8.6M | −$8.4M | −$6.1M | −$6.3M | −$3.5M | −$3.0M | −$5.1M | −$3.1M | −$2.0M | −$1.8M | — |
| EBITDA margin | −8,498.85% | −26,267.67% | — | — | −42,778.38% | — | — | — | — | — | — | — | — | −1,777.70% | — |
| Net income | −$13.4M | −$7.8M | −$8.7M | −$8.8M | −$9.1M | −$11.5M | −$14.6M | −$10.0M | −$6.1M | −$5.8M | $680,811 | −$10.1M | −$3.2M | −$2.7M | −$7.1M |
| Net profit margin | −8,513.44% | −28,127.25% | — | — | −45,528.65% | — | — | — | — | — | — | — | — | −2,629.30% | −8,609.82% |
| Basic EPSper basic share | -$4.23 | -$4.60 | -$5.58 | -$6.90 | -$9.60 | -$19.20 | -$43.20 | -$33.60 | -$24.00 | -$19.20 | $4.80 | -$43.20 | -$14.40 | -$14.40 | -$38.40 |
| Diluted EPSper diluted share | -$4.23 | -$4.60 | -$5.58 | -$6.90 | -$9.60 | -$19.20 | -$43.20 | -$33.60 | -$24.00 | -$19.20 | $4.80 | -$43.20 | -$14.40 | -$14.40 | -$38.40 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
YALDOO LAITH L | 583.62K |
STROME INVESTMENT MANAGEMENT LP / STROME MARK E / STROME GROUP, INC. | 572.94K |
Maggiore Christopher D. | 519.29K |
Cornell Alison A | 279.48K |
Masterson Nola E | 130.91K |
PAYNE JOHN BERNARD | 19.62K |
CoreCap Advisors, LLC | 4.36K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 17, 2026Form 4 | STROME INVESTMENT MANAGEMENT LP +2Other | BuyCommon Stock · indirect | 100.0K | $2.00 | $200.0K | 572.9K |
| Feb 27, 2026Form 4 | YALDOO LAITH LDirector,TenPercentOwner | BuyCommon Stock · indirect | 1.5K | $9.72 | $15.0K | 583.6K |
| Feb 12, 2026Form 4 | STROME GROUP, INC. +2Other | BuyCommon Stock · indirect | 20.0K | $9.77 | $195.4K | 472.9K |
| Feb 12, 2026Form 4 | STROME GROUP, INC. +2Other | BuyCommon Stock Purchase Warrant · derivative · indirect | 2.0K | $0.00 | $0.00 | 45.1K |
| Feb 10, 2026Form 4 | YALDOO LAITH LDirector,TenPercentOwner | BuyCommon Stock · indirect | 2.4K | $10.27 | $25.0K | 582.1K |